| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.083 | 0.06 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.06 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.06 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.06 |